ANDA 213248, held by Alembic. Lurasidone Hydrochloride.
As of Nov 16, 2026, ANDA 213248 (Lurasidone Hydrochloride), held by Alembic, was first approved by FDA on May 13, 2021, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 13, 2021 | Original application | Approved | None posted |
| Lurasidone Hydrochloride20MG · tablet;oral | Lurasidone Hydrochloride | Rx |
| Lurasidone Hydrochloride40MG · tablet;oral | Lurasidone Hydrochloride | Rx |
| Lurasidone Hydrochloride60MG · tablet;oral | Lurasidone Hydrochloride | Rx |
| Lurasidone Hydrochloride80MG · tablet;oral | Lurasidone Hydrochloride | Rx |
| Lurasidone Hydrochloride120MG · tablet;oral | Lurasidone Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters